0.82
-1.45%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biosynex
Its shares trade on Euronext Paris under the ticker ALBIO.PA. It has been listed since 21 March 2011. In the fiscal year to 31 December 2025, it reported revenue of €95.2m and a net loss of €58.2m. At that date it held total assets of €136.2m and shareholders' equity of €32.4m.
Biosynex SA engages in the development of practical diagnostics in order to prevent, diagnose and enable appropriate patient care management. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 21 Mar 2011
- Employees
- 144
- Website
- biosynex.com ↗
Leadership
Pay as last reported
- Mr. Larry AbensurChief Executive Officer, Director, since 2005
- Mr. Thomas LamyDeputy Chief Executive Officer, Director, since 2015
- Mr. Thierry PaperDeputy Chief Executive Officer - Research and Business development, Administrator, since 2005€117,600
- Mr. Elie FraenckelDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Reputation: Biosynex SA has built a strong reputation in the market for its reliable and high-quality medical diagnostics products.
- Innovative Product Range: The company offers a diverse range of innovative diagnostic tests and kits, catering to various medical needs.
- Strong Distribution Network: Biosynex has a wide distribution network, enabling it to reach healthcare professionals and consumers efficiently.
Weaknesses
- Dependence on External Suppliers: Biosynex relies on external suppliers for certain components, posing a risk for supply chain disruptions.
- Limited Global Presence: The company's market presence is primarily focused on Europe, limiting its exposure to potential growth opportunities in other regions.
- Relatively Small Scale: Compared to larger competitors, Biosynex operates on a smaller scale, which may limit its ability to compete in terms of economies of scale.
Opportunities
- Growing Demand for Diagnostic Tests: The increasing global focus on healthcare and disease prevention presents an opportunity for Biosynex to expand its customer base.
- Emerging Markets: The company can explore and expand into emerging markets, leveraging its expertise and product portfolio.
- Strategic Partnerships: Collaborating with other healthcare companies or research institutions can help Biosynex develop innovative solutions and expand its market reach.
Threats
- Intense Competition: The medical diagnostics industry is highly competitive, with both established players and new entrants vying for market share.
- Regulatory Challenges: Adhering to evolving regulatory standards and obtaining necessary approvals for products can pose challenges and impact time-to-market.
- Economic Factors: Economic fluctuations, pricing pressures, and healthcare budget constraints can affect demand for Biosynex's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.